New biomarker for identification of coronary artery disease patients at high risk for cardiovascular death

Zora Biosciences in collaboration with academic research groups from Finland, Germany, Austria,  Switzerland and Norway have shown that plasma ceramides are significant predictors of cardiovascular death both in patients with stable CAD and ACS over and above currently used lipid markers such as LDL-cholesterol. This may improve the identification of high-risk patients in need of more aggressive therapeutic interventions including more frequent follow-up visits and efficient life-style counselling as well as the consideration for higher statin doses, ezetimibe combinations, or novel therapies such as PCSK9 inhibitors.

Read the publication here.